DDReg pharma

Quailty Driven by Passion

Author name: development

Role of Pharmacovigilance Audits in Drug safety

Pharmacovigilance Audits: Ensuring Drug Safety

Edit with Elementor Loading Behind every safe and effective medicine on the market lies a complex system of checks and balances and key parameter of that system are pharmacovigilance (PV) audits. While they might not grab headlines like clinical trials or breakthrough approvals, PV audits are the quiet guardians of drug safety, ensuring that pharmaceutical […]

Pharmacovigilance Audits: Ensuring Drug Safety Read More »

Data privacy in Global clinical trials

Data Privacy Regulations in Global Clinical Trials: What You Need to Know 

Imagine volunteering for a clinical trial sharing your medical history, personal habits, and even your genetic data, all for advancing science. Now imagine that data falling into the wrong hands. In an age where data is as valuable as the therapies being developed, data privacy in clinical trials has become a keystone of ethical research

Data Privacy Regulations in Global Clinical Trials: What You Need to Know  Read More »

Regulatory Pathways for Cell-Based Therapies in Oncology 

Cell-based therapies in oncology represent a transformative approach to cancer treatment. By leveraging the power of living cells often from the patient’s own immune system—these therapies are designed to precisely target and eliminate cancer cells. Notable examples include chimeric antigen receptor (CAR) T cell therapy, where a patient’s T cells (a type of immune cell)

Regulatory Pathways for Cell-Based Therapies in Oncology  Read More »

Key Strategies & Considerations in Remote Regulatory Inspections

Preparing for Remote Regulatory Inspections: Key Strategies & Considerations 

The COVID-19 pandemic catalyzed a shift in how regulatory authorities conduct inspections, accelerating the adoption of remote regulatory inspections (RRIs) as a pragmatic alternative to traditional onsite audits. While initially a contingency approach, RRIs have now evolved into a sustainable model widely accepted by health authorities such as the U.S. FDA, EMA, MHRA, and Health

Preparing for Remote Regulatory Inspections: Key Strategies & Considerations  Read More »

Case study on Pharmacovigilance Auditing Project

PV System Audit Uncovers Gaps, Boosts Readiness

Customer Requirement A multinational pharmaceutical corporation (MNC) engaged in the manufacturing of therapeutics, food supplements, nutrition products, and treatments for nervous and respiratory systems, approached DDReg to conduct a comprehensive audit of its pharmacovigilance (PV) system. The audit was focused on evaluating the PV system being maintained at the company’s headquarters. The client also sought

PV System Audit Uncovers Gaps, Boosts Readiness Read More »

One Health veterinary regulations ensuring animal and public health.

One Health Framework in Veterinary Medicine & Regulations 

In recent years, regulatory conversations within the life sciences sector have increasingly emphasized the importance of a unified approach to human, animal, and environmental health what is now commonly referred to as the One Health framework. Far from being a conceptual model, One Health has become a practical foundation influencing regulatory policies worldwide, particularly in

One Health Framework in Veterinary Medicine & Regulations  Read More »

Regulatory Support for Cosmetics Products in Latin America

Regulatory Standards for Cosmetics in Latin America 

Latin America (LATAM) is one of the fastest-growing regions for cosmetics, with annual growth rates often surpassing global averages. Among its key markets, Brazil stands out as the largest, followed closely by Mexico, Argentina, Colombia, and others. However, for companies aiming to manufacture or export cosmetic products to LATAM, understanding the region’s fragmented regulatory processes

Regulatory Standards for Cosmetics in Latin America  Read More »

Regulatory Query Support with Expert PK Reanalysis & Justification

Addressing Regulatory Query with Expert PK Reanalysis & Justification 

Customer Requirement A pharmaceutical company specializing in generic drug development was in the process of seeking market approval for a generic product. During the regulatory review process, the benefit-risk department of the regulatory authority raised a query related to the statistical analysis of the submitted bioequivalence (BE) study data. The company required a comprehensive and

Addressing Regulatory Query with Expert PK Reanalysis & Justification  Read More »